Barclays downgraded Sangamo (SGMO) to Equal Weight from Overweight with a price target of $1, down from $5. The company’s Q3 report highlighted the FDA’s reaffirmation of an accelerated approval path using eGFR slope as the endpoint and its cash runway has been extended into Q1 of 2026, the analyst tells investors in a research note. Barclays steps to the sidelines pending further clarity on a Fabry deal.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMO: